|
|
|
Biological Activity:
Potent and selective tyrosine kinase (Trk) inhibitor with IC50 to 2 and 8 nM for TrkA and TrkB respectively; AZ-23 showed in vivo TrkA kinase inhibition and efficacy in mice following oral administration; having potential for therapeutic utility in neuroblastoma and multiple other cancer indications.
References:
K Thress et al. Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway. Mol Cancer Ther 2009, 8(7), 1818-1827. [online]
Chemical Name: 5-chloro-N-[(1S)-1-(5-fluoropyridin-2-yl)ethyl]-N′-(5-propan-2-yloxy-1H-pyrazol-3-yl)pyrimidine-2,4-diamine
|
| AZ 23 | Trk inhibitor | Axon Medchem | Axon 1610 | AZ23 |
|
Axon Ligands TM - Research chemicals for biological study. Some high-profile samples could be provided under terms of contract research synthesis.
axonmedchem.com © 2011 |
![]() |
Axon Ligands in the field:
AZ 23 | Trk inhibitor
GW 441756 | TrkA inhibitor
Click Here To See Featured Cell Signaling and Oncology Ligands from Axon Ligands Collection
About Trk:
Tropomyosin-related kinases (TrkA, TrkB, and TrkC) are a family of receptor tyrosine kinases activated by neurotrophins. Trks play important roles in pain sensation as well as tumour cell growth and survival signaling.
|
